Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 19 (6) , e683-e689
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 39 references indexed in Scilit:
- Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyAnnals of Oncology, 2012
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment, 2011
- Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?The Annals of The Royal College of Surgeons of England, 2011
- Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline featuresBreast Cancer Research and Treatment, 2010
- The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant ChemotherapyAnnals of Surgical Oncology, 2010
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant TherapyJournal of Clinical Oncology, 2008
- Letrozole in the neoadjuvant setting: the P024 trialBreast Cancer Research and Treatment, 2007
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancerBritish Journal of Cancer, 2002